SCHEMBL7765052

SCHEMBL7765052

NC(=O)CC(CCC(Cl)c1ccccc1)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.43
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
PKM P14618 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
EPHX1 P07099 1/20 0.40
SLC6A3 Q01959 3/20 0.39
DRD3 P35462 2/20 0.39
LMNA P02545 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
EDNRB P24530 1/20 0.39
MAPK1 P28482 1/20 0.39
MC4R P32245 1/20 0.39
MC3R P41968 1/20 0.39
DRD2 P14416 1/20 0.39
GRM2 Q14416 2/20 0.38
GRM3 Q14832 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GABBR2 O75899 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6402185 0.81 SLC6A3 (0.52) CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2
SCHEMBL6404252 0.78 CYP2D6 (0.46) CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2
Acetamide SCHEMBL27959240 0.76 CYP2C19 (0.47) CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2
SCHEMBL22042229 0.74 TSHR (0.55)
Phthalic Acid SCHEMBL28972902 0.73 ALDH1A1 (0.48) CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2
SCHEMBL7360868 0.72 GRIK1 (0.56) SMN1; SMN2SLC6A3LMNAMAPK1ALDH1A1
SCHEMBL637452 0.71 CYP2C19 (0.53) CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2
SCHEMBL1231305 0.71 CYP2C19 (0.53) CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2
SCHEMBL637029 0.71 CYP2C19 (0.53) CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2
SCHEMBL7428193 0.71 PARP10 (0.50) PKMSMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed